Transcatheter Heart Valve Market size was valued at US$ 6.33 Billion in 2020 and is expected to grow US$ 24.04 Billion by 2027 at a CAGR of 21% during the forecast period. Transcatheter heart valves (THV) are used to replace the heart valves with a prosthetic valve for treatment of severe aortic stenosis and mitral regurgitation. These heart valve diseases can be congenital or acquired later in life due to age related life style changes and may be other underlying diseases. If these are not treated can cause heart failure, stroke, blood clots, or death due to sudden cardiac arrest. In June 2017, U.S. FDA approved Edwards Sapien 3 transcatheter heart valve (by Edwards Lifesciences Corporation), a transcatheter heart valve replacement deviceTranscatheter Heart Valve Market report gives a comprehensive outlook across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of product type, surgical procedure type, end-user and region. This report market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global Transcatheter Heart Valve.